Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats

Miller, W. , Brosnan, M.J., Graham, D., Nicol, C.G., Morecroft, I., Channon, K.M., Danilov, S.M., Reynolds, P.N., Baker, A.H. and Dominiczak, A.F. (2005) Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats. Molecular Therapy, 12(2), pp. 321-327. (doi:10.1016/j.ymthe.2005.02.025)

Miller, W. , Brosnan, M.J., Graham, D., Nicol, C.G., Morecroft, I., Channon, K.M., Danilov, S.M., Reynolds, P.N., Baker, A.H. and Dominiczak, A.F. (2005) Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats. Molecular Therapy, 12(2), pp. 321-327. (doi:10.1016/j.ymthe.2005.02.025)

Full text not currently available from Enlighten.

Abstract

Local adenoviral (Ad)-mediated gene transfer to the carotid artery of the stroke-prone spontaneously hypertensive rat (SHRSP) is successful in improving endothelial function. Here we explored the potential of systemic delivery of Ad encoding endothelial nitric oxide synthase (AdeNOS) to prevent elevation of blood pressure in the SHRSP using both nontargeted and vector targeting approaches. Systemic administration of nontargeted AdeNOS failed to modify the rise in blood pressure in SHRSP when administered during the 12th week of age (n = 5, P = 0.088, F = 3.0), an effect likely to result from sequestration of Ad by the liver. Rerouting Ad transduction using a bispecific antibody (anti-ACE/anti-Ad capsid, Fab9B9) that blocks Ad binding to the coxsackie and adenovirus receptor and simultaneously retargets AdeNOS to the angiotensin-converting enzyme resulted in efficient eNOS overexpression in the lung vasculature and a sustained hypotensive effect (n = 5, P = 0.007, F = 7.9). This study highlights the importance of vector targeting to achieve therapeutic gain and represents the first such study in cardiovascular gene therapy.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Miller, Dr William and Dominiczak, Professor Anna and Baker, Professor Andrew
Authors: Miller, W., Brosnan, M.J., Graham, D., Nicol, C.G., Morecroft, I., Channon, K.M., Danilov, S.M., Reynolds, P.N., Baker, A.H., and Dominiczak, A.F.
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Molecular Therapy
Publisher:Nature Publishing Group
ISSN:1525-0016
ISSN (Online):1525-0024

University Staff: Request a correction | Enlighten Editors: Update this record